Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Executive Summary
Pink Sheet’s Drug Review Profile looks at US FDA clinical memos opposing approval of Sarepta's Duchenne muscular dystrophy drug eteplirsen, revealing challenges patient advocates and agency face in transforming patient experiences into hard data that can be used for approvals.